Picture of Albion Technology & General VCT logo

AATG — Albion Technology & General VCT News Story

0.000.00%
gb flag iconLast trade - 00:00
FinancialsConservativeSmall CapFalling Star

Half-yearly Financial Report

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230921:nGNE7W0KdJ&default-theme=true


Albion Technology & General VCT PLC
LEI number: 213800TKJUY376H3KN16

As required by the UK Listing Authority's Disclosure Guidance and Transparency
Rule 4.2, Albion Technology & General VCT PLC today makes public its
information relating to the Half-yearly Financial Report (which is unaudited)
for the six months to 30 June 2023. This announcement was approved by the
Board of Directors on 21 September 2023.

The full Half-yearly Financial Report (which is unaudited) for the period to
30 June 2023, will shortly be sent to shareholders. Copies of the full
Half-yearly Financial Report will be shown via the Albion Capital Group LLP
website by clicking www.albion.capital/funds/AATG/30Jun23.pdf.

Investment objective and policy

The Company’s investment objective is to provide investors with a regular
and predictable source of dividend income, combined with the prospect of
long-term capital growth, through a balanced portfolio of predominantly
unquoted growth and technology businesses in a qualifying Venture Capital
Trust (“VCT”).

Investment policy

The Company will invest in a broad portfolio of unquoted growth and technology
businesses. Allocation of assets will be determined by the investment
opportunities which become available, but efforts will be made to ensure that
the portfolio is diversified in terms of sectors and stages of maturity of
portfolio companies.

VCT qualifying and non-qualifying investments

Application of the investment policy is designed to ensure that the Company
continues to qualify and is approved as a VCT by HM Revenue and Customs
(“VCT regulations”). The maximum amount invested in any one company is
limited to HMRC annual investment limits. It is intended that normally at
least 80% of the Company's funds will be invested in VCT qualifying
investments. The VCT regulations also have an impact on the type of
investments and qualifying sectors in which the Company can make an
investment.

Funds held either prior to investing in VCT qualifying assets or for liquidity
purposes will be held as cash on deposit, invested in floating rate notes or
similar instruments with banks or other financial institutions with high
credit ratings or invested in liquid open-ended equity funds providing income
and capital equity exposure (where it is considered economic to do so).
Investment in such open-ended equity funds will not exceed 7.5% of the
Company’s assets at the time of investment.

Risk diversification and maximum exposures

Risk is spread by investing in a number of different businesses within VCT
qualifying industry sectors using a mixture of securities. The maximum the
Company will invest in a single company is 15% of the Company’s assets at
cost at the time of investment. The value of an individual investment is
expected to increase over time as a result of trading progress and a
continuous assessment is made of investments' suitability for sale. It is
possible that individual holdings may grow in value to a point where they
represent a significantly higher proportion of total assets prior to a
realisation opportunity being available.

Borrowing powers

The Company’s maximum exposure in relation to gearing is restricted to 10%
of the adjusted share capital and reserves. The Directors do not have any
intention of utilising long-term gearing.

Financial calendar

 Record date for second dividend for the year   Payment date for second dividend for the year   Financial year end  8 December 2023   29 December 2023   31 December  

Financial summary

                                    Unaudited six months ended 30 June 20 2 3 (pence per share)  Unaudited six months ended 30 June 2022 (pence per share)  Audited year ended 31 December 2022 (pence per share)  
 Opening net asset value            72.92                                                        80.65                                                      80.65                                                  
 Capital return/(loss)              4.59                                                         (0.10)                                                     (4.51)                                                 
 Revenue return                     0.1 5                                                        0.11                                                       0. 46                                                  
 Total return/(loss)                4.74                                                         0.01                                                       (4.05)                                                 
 Dividends paid                     ( 1.82 )                                                     (2.02)                                                     (3.99)                                                 
 Impact of share capital movements  0.18                                                         0.05                                                       0.3 1                                                  
 Net asset value                    76.02                                                        78.69                                                      72.92                                                  



 Total shareholder value  Ordinary shares (pence per share)         
 Total dividends paid since inception            125.44             
 Net asset value as at 30 June 2023              76.02              
 Total shareholder value to 30 June 202 3        201.46             

In addition to the dividends paid above, the Board declared a second dividend
for the year ending 31 December 2023 of 1.90 pence per Ordinary share to be
paid on 29 December 2023 to shareholders on the register on 8 December 2023.

Further details regarding the total shareholder value for the historic C
Shares, Albion Income and Growth VCT PLC and Ordinary shares, as well as the
dividend record from inception of the Company in 2000, can be found at
www.albion.capital/funds/AATG under the ‘Financial Summary for Previous
Funds’ section.

Interim management report

Introduction
I am pleased to report a strong positive total return for the six months ended
30 June 2023 of 4.74 pence per share which represents a 6.5% return on opening
net asset value. We continue to see resilience and revenue growth from many of
our portfolio companies despite the difficult macroeconomic and geopolitical
backdrop, including continuing high inflation, rising interest rates and
volatility of quoted technology company valuations.

Results and dividends 
The net asset value per Ordinary share as at 30 June 2023 has increased by
4.3% to 76.02 pence over the six months (30 June 2022: 78.69 pence; 31
December 2022: 72.92 pence) mainly due to the valuation uplift in Quantexa,
discussed below.

In line with our dividend policy, targeting around 5% of NAV per annum, the
Company paid a dividend of 1.82 pence per share during the period to 30 June
2023 (30 June 2022: 2.02 pence per share). The Company will pay a second
dividend for the financial year ending 31 December 2023 of 1.90 pence per
share on 29 December 2023 to shareholders on the register on 8 December 2023,
being 2.5% of the latest reported NAV at 30 June 2023.

This will bring the total dividends paid for the year ending 31 December 2023
to 3.72 pence per share, which equates to a 5.1% yield on the opening NAV of
72.92 pence per share at 31 December 2022.

Performance and portfolio update
The total gain on investments for the period ended 30 June 2023 was £9.4
million (six months ended 30 June 2022: gain of £1.6 million; year ended 31
December 2022: loss of £4.5 million). The key movement in the period was an
£11.4 million valuation uplift to the Quantexa holding following an
externally led $129 million Series E fundraising which completed in April
2023. The latest funding round made the company the first UK “Unicorn” of
2023 (a private company valuation over $1 billion) and the Board remain
excited about its prospects. Other gains in the period, which were driven by
revenue growth, included unrealised gains in Radnor House School of £0.8
million and Ophelos of £0.4 million.

These gains were offset by write downs in Black Swan Data which decreased by
£2.2 million, Locum’s Nest by £0.4 million and Speechmatics by £0.4
million.

The Company realised disposal proceeds of £1.0 million, the largest disposals
being Zift (£0.5 million) and a part disposal of our shareholding in our
quoted investment, Arecor Therapeutics PLC (£0.2 million). Further details of
other realisations during the period can be found in the realisations table
below. 

During the period, a total of £0.4 million was deployed as follow-on
investments into the existing portfolio, including £0.3 million into Proveca
and £0.1 million into Seldon Technologies. The economic uncertainty, high
inflation rates and rising interest rates have resulted in a quiet period of
investment in the first half of 2023. However, there is a growing pipeline of
new investments, and investment activity has started to increase after the
period end, with £1.8 million invested at the date of this report into new
and follow-on investments since 30 June 2023.

Our top 3 portfolio companies now account for 29.2% of the Company’s NAV (30
June 2022: 21.6%; 31 December 2022: 22.2%). Further details of the portfolio
of investments can be found below.

Current portfolio sector allocation
Set out at the bottom of this announcement is the sector diversification of
the portfolio of investments as at 30 June 2023.

Board composition and succession planning
During the period Robin Archibald retired after nine years on the Board,
including two as Chairman and seven as Audit Committee Chairman. On behalf of
the Board and the Manager, I would like to thank and note my appreciation to
Robin for his invaluable contribution and wise guidance and leadership
throughout his time as a Director. As announced on 18 May 2023, Mary Anne
Cordeiro, having served a similar period, also retired during the period. The
Board and the Manager would like to thank her for her strong contribution. In
particular, her support and advice has been hugely appreciated. We wish both
Robin and Mary Anne well in their future endeavours.

As part of the Board’s succession planning, we were pleased to welcome David
Benda as a Director with effect from 26 June 2023, and Peter Moorhouse from 1
September 2023. David has extensive corporate banking experience working with
investment companies providing advice on fundraising, reorganisations and
restructurings. Peter brings a depth of corporate finance knowledge
particularly with companies in the healthcare and technology sectors, advising
primarily on equity financing, mergers and acquisitions.

The Nomination Committee continually monitors and reviews the membership of
the Board based on the spread of skills and contributions of its members, as
well as looking at succession planning requirements of the Company. The
Company has made several changes to the Board in recent years and continues to
review actively Board succession.

Share buy-backs 
It remains the Board’s policy to buy-back shares in the market, subject to
the overall constraint that such purchases are in the Company’s interest.
This includes the maintenance of sufficient cash resources for investment in
new and existing portfolio companies and the continued payment of dividends to
shareholders.

It is the Board’s intention that such buy-backs should be at around a 5%
discount to NAV, in so far as market conditions and liquidity permit. The
Company purchased 2,117,126 Ordinary shares for treasury during the period at
a total cost of £1.6 million (30 June 2022: £1.2 million; 31 December 2022:
£2.5 million). The Company continues to conduct active buy-backs to help
provide good secondary market liquidity for those who want to dispose of all
or part of their shareholdings.

Risks and uncertainties 
The Company faces a number of significant risks including rising interest
rates, high levels of inflation, the ongoing impact of geopolitical tensions,
and an expected period of economic stagnation in the UK and other markets. The
concentration risk to the technology sector is noted as technology company
valuations have become more uncertain in the current economic climate. The
Manager continually assesses the exposure to these risks for each portfolio
company and appropriate actions, where possible, are implemented.

In accordance with Disclosure Guidance and Transparency rules (“DTR”), the
Board confirms that the principal risks and uncertainties facing the Company
have not changed materially from those identified in the Annual Report and
Financial Statements for the year ended 31 December 2022. There is heightened
uncertainty, but this has not changed the nature of the principal risks. The
Board considers that the present processes for mitigating those risks remain
appropriate.

The principal risks faced by the Company are:
* Investment, performance and valuation risk;
* VCT approval risk;
* Cyber and data security risk;
* Reliance on key agents and personnel risk;
* Economic, political and social risk; and
* Discount risk.
A detailed analysis of the principal risks and uncertainties facing the
business can be found in the Annual Report and Financial Statements for the
year ended 31 December 2022 on pages 24 to 26, copies of which are available
on the Company’s webpage on the Manager’s website at
www.albion.capital/funds/AATG under the ‘Financial Reports and Circulars’
section.

Albion VCTs Prospectus Top Up Offers
The 2022/23 Offers were fully subscribed and closed having raised £15.5
million for the Company. The Board was pleased to see the high level of demand
for the Company’s shares from existing and new shareholders.

The proceeds of the Offers are being used to provide support to our existing
portfolio companies and to enable us to take advantage of new investment
opportunities as they arise. Details of the share allotments during the period
can be found in note 8.

Transactions with the Manager
Details of the transactions that took place with the Manager in the period can
be found in note 5. Details of related party transactions can be found in note
12.

Shareholder seminar
The Board is pleased to report that the Manager, Albion Capital, will host a
shareholder seminar this year on 15 November 2023 at the Royal College of
Surgeons. The Board considers this an important part of shareholder
communication as it provides an opportunity for shareholders to interact with
the Board and the Manager; shareholders are encouraged to attend. Places are
limited and to reserve a place please email info@albion.capital with subject
heading “Shareholder Seminar” and include your full name. You will receive
an email confirmation of your place, subject to availability.

Move to electronic communications
The Board wishes to minimise the environmental impact of how the Company
communicates with its shareholders. With this in mind, those shareholders that
continue to receive physical copies of the Annual Report and other
documentation, will receive a letter alongside this Half-yearly Financial
Report explaining the forthcoming move to electronic communications.

Outlook
Although there remain many uncertainties facing the Company, with the high
levels of inflation, elevated interest rates and geopolitical tensions, the
results for the period demonstrate the resilience of our portfolio during
these challenging times. Our strategy is to focus on dynamic sectors with long
term growth prospects such as technology and healthcare within which we
maintain a diversified portfolio in terms of companies at different stages of
maturity and across a variety of sub sectors. We remain confident that the
Company will continue to provide positive results to its shareholders over the
long-term.

Clive Richardson
Chairman
21 September 2023

Portfolio of investments

                                                                  As at 30 June 20 2 3                                                                                               
 Portfolio company                               % voting rights  Cost £’000     Cumulative movement in value £’000     V alue £’000       Change in value for the period* £’000     
 Quantexa                                        2.4              2,740          25,601                                 28,341             11,408                                    
 Radnor House School (TopCo)                     14.8             2,710          3,375                                  6,085              840                                       
 Proveca                                         7.2              1,438          3,648                                  5,086              103                                       
 Chonais River Hydro                             15.7             2,169          2,161                                  4,330              296                                       
 Oviva                                           2.9              2,694          1,220                                  3,914              (388)                                     
 Cantab Research (T/A Speechmatics)              3.4              2,901          510                                    3,411              (407)                                     
 The Evewell Group                               6.4              1,547          1,613                                  3,160              23                                        
 Egress Software Technologies                    2.2              765            2,136                                  2,901              (57)                                      
 Runa Network                                    3.3              2,101          591                                    2,692              -                                         
 Gharagain River Hydro                           18.5             1,526          1,003                                  2,529              214                                       
 Elliptic Enterprises                            1.6              2,156          -                                      2,156              -                                         
 Convertr Media                                  6.9              1,105          1,017                                  2,122              (39)                                      
 Healios                                         2.5              1,500          416                                    1,916              -                                         
 MHS 1                                           22.5             1,565          93                                     1,658              -                                         
 Panaseer                                        3.1              1,122          532                                    1,654              (283)                                     
 TransFICC                                       2.7              1,275          377                                    1,652              -                                         
 Peppy Health                                    1.6              1,481          -                                      1,481              -                                         
 The Street by Street Solar Programme            8.1              895            563                                    1,458              (86)                                      
 Threadneedle Software Holdings (T/A Solidatus)  1.7              1,014          408                                    1,422              (208)                                     
 Toqio FinTech Holdings                          2.0              1,400          -                                      1,400              -                                         
 InCrowd Sports                                  4.8              749            506                                    1,255              192                                       
 Regenerco Renewable Energy                      7.9              822            382                                    1,204              (117)                                     
 Gravitee Topco (T/A Gravitee.io)                2.2              920            235                                    1,155              -                                         
 Beddlestead                                     9.8              1,200          (127)                                  1,073              (43)                                      
 Aridhia Informatics                             4.9              950            73                                     1,023              (153)                                     
 PeakData                                        2.1              943            56                                     999                (15)                                      
 The Q Garden Company                            33.4             934            65                                     999                -                                         
 Ophelos                                         1.9              492            412                                    904                411                                       
 GX Molecular (T/A CS Genetics)                  2.9              846            -                                      846                -                                         
 Seldon Technologies                             2.3              796            -                                      796                -                                         
 NuvoAir Holdings                                1.4              564            231                                    795                (41)                                      
 Locum’s Nest                                    6.9              813            (70)                                   743                (439)                                     
 Alto Prodotto Wind                              6.9              509            232                                    741                34                                        
 Cisiv                                           5.3              695            29                                     724                311                                       
 OutThink                                        2.7              687            -                                      687                -                                         
 PerchPeek                                       2.0              635            -                                      635                -                                         
 Diffblue                                        2.5              585            -                                      585                -                                         
 Premier Leisure (Suffolk)                       -                454            90                                     544                -                                         
 Accelex Technology                              2.0              353            191                                    544                191                                       
 PetsApp                                         2.6              487            -                                      487                -                                         
 Erin Solar                                      15.7             440            12                                     452                -                                         
 DySIS Medical                                   2.6              2,589          (2,167)                                422                30                                        
 5Mins AI                                        2.2              390            -                                      390                -                                         
 Imandra                                         1.6              215            101                                    316                (15)                                      
 AVESI                                           8.0              259            55                                     314                (33)                                      
 Brytlyt                                         1.9              406            (96)                                   310                (95)                                      
 Koru Kids                                       1.3              430            (121)                                  309                (52)                                      
 Ramp Software                                   1.9              277            -                                      277                -                                         
 Arecor Therapeutics PLC                         0.4              149            124                                    273                (9)                                       
 Neurofenix                                      2.9              590            (334)                                  256                (334)                                     
 Tem-Energy                                      1.9              241            -                                      241                -                                         
 Harvest AD                                      -                210            23                                     233                -                                         
 uMedeor (T/A uMed)                              0.9              150            53                                     203                51                                        
 Mirada Medical                                  4.6              1,321          (1,125)                                196                -                                         
 Regulatory Genome Development                   0.8              118            40                                     158                40                                        
 Greenenerco                                     3.1              77             59                                     136                7                                         
 Infact Systems (T/A Infact)                     1.9              96             -                                      96                 -                                         
 Symetrica                                       0.2              91             (6)                                    85                 11                                        
 Black Swan Data                                 8.3              4,714          (4,648)                                66                 (2,195)                                   
 uMotif                                          3.6              1,121          (1,120)                                1                  (119)                                     
 Limitless Technology                            2.1              560            (560)                                  -                  (282)                                     
 Elements Software                               -                19             (19)                                   -                  -                                         
                                                                                                                                                                                     
 Total fixed asset investments                                    63,001         37,8 4 0                               100,841            8,752                                     

T/A – trading as
* As adjusted for additions and disposals during the period.

 Investment realisations in the period to 30 June 20 2 3  Cost £’000     Opening carrying value £’000     Disposal proceeds £’000     Total realised gain /(loss) £’000     G ain /(loss) on opening value £’000     
 Disposals:                                                                                                                                                                                                          
 Zift Channel Solutions                                   881            326                              464                         (417)                                 138                                      
 Arecor Therapeutics PLC                                  82             154                              160                         78                                    6                                        
 Oxsensis                                                 3,484          95                               109                         (3,375)                               14                                       
 Forward Clinical (T/A Pando)                             196            -                                -                           (196)                                 -                                        
                                                                                                                                                                                                                     
 Loan stock repayments and other :                                                                                                                                                                                   
 Alto Prodotto Wind                                       20             31                               31                          11                                    -                                        
 Greenenerco                                              4              5                                5                           1                                     -                                        
 Escrow adjustments and other*                            -              -                                209                         209                                   209                                      
 Total                                                    4,66 7         611                              978                         (3, 689 )                             367                                      

* These comprise fair value movements on deferred consideration on previously
disposed investments and expenses which are incidental to the purchase or
disposal of an investment

                                                                                                      £’000     
 Total change in value of investments for the year                                                    8,752     
 Movement in loan stock accrued interest                                                              35        
 Unrealised gains on fixed asset investments sub-total                                                8,787     
 Realised gains on fixed asset investments                                                            367       
 Finance income from the unwinding of discount on deferred consideration                              208       
 Total gains on investments as per Income statement                                                   9,362     

Responsibility statement

The Directors, Clive Richardson, Margaret Payn, David Benda, Peter Moorhouse
and Patrick Reeve, are responsible for preparing the Half-yearly Financial
Report. In preparing these condensed Financial Statements for the period to 30
June 2023 we, the Directors of the Company, confirm that, to the best of our
knowledge:

(a) the condensed set of Financial Statements, which has been prepared in
accordance with Financial Reporting Standard 104 “Interim Financial
Reporting”, gives a true and fair view of the assets, liabilities, financial
position and profit and loss of the Company as required by DTR 4.2.4R;

(b) the Interim management report includes a fair review of the information
required by DTR 4.2.7R (indication of important events during the first six
months and description of principal risks and uncertainties for the remaining
six months of the year); and

(c) the Interim management report includes a fair review of the information
required by DTR 4.2.8R (disclosure of related parties’ transactions and
changes therein).

This Half-yearly Financial Report has not been audited or reviewed by the
Auditor.

For and on behalf of the Board

Clive Richardson
Chairman 
21 September 2023

Condensed income statement

                                                                                    Unaudited six months ended 30 June 2023           Unaudited six months ended 30 June 2022             Audited year ended 31 December 2022                 
                                                                              Note  Revenue         Capital £’000     Total £’000     Revenue £’000     Capital £’000     Total £’000     Revenue £’000     Capital £’000     Total £’000     
                                                                                    £’000                                                                                                                                                     
 Gains/(losses) on investments                                                3     -               9,362             9,362           -                 1,579             1,579           -                 (4,480)           (4,480)         
 Investment income                                                            4     713             -                 713             619               -                 619             1,631             -                 1,631           
 Investment Manager’s fees*                                                   5     ( 1 3 8 )       ( 1, 45 7 )       ( 1, 59 5 )     (129)             (1,725)           (1,854)         (253)             (2,541)           (2,794)         
 Other expenses                                                                     ( 32 1 )        -                 ( 32 1 )        (327)             -                 (327)           (658)             -                 (658)           
 P rofit /(loss) on ordinary activities before tax                                  25 4            7,90 5            8,159           163               (146)             17              720               (7,021)           (6,301)         
 Tax charge on ordinary activities                                                  -               -                 -               -                 -                 -               -                 -                 -               
 P rofit /(loss) and total comprehensive income attributable to shareholders        25 4            7,90 5            8,159           163               (146)             17              720               (7,021)           (6,301)         
 Basic and diluted return /(loss) per share (pence)* *                        7     0.1 5           4.59              4.74            0.11              (0.10)            0.01            0.46              (4.51)            (4.05)          

* For more information on the allocation between revenue and capital please
see the accounting policies below
** adjusted for treasury shares

Comparative figures have been extracted from the unaudited Half-yearly
Financial Report for the six months ended 30 June 2022 and the audited
statutory accounts for the year ended 31 December 2022.

The accompanying notes form an integral part of this Half-yearly Financial
Report.

The total column of this Condensed income statement represents the profit and
loss account of the Company. The supplementary revenue and capital columns
have been prepared in accordance with The Association of Investment
Companies’ Statement of Recommended Practice.

Condensed balance sheet

                                                                         Note  Unaudited 30 June 20 2 3 £’000     Unaudited 30 June 2022 £’000     Audited 31 December 2022 £’000     
 Fixed asset investments                                                       100,841                            89,519                           92,301                             
                                                                                                                                                                                      
 Current assets                                                                                                                                                                       
 Trade and other receivables                                                   3, 4 19                            3,221                            3,456                              
 Cash in bank and at hand                                                      32,906                             35,518                           26,594                             
                                                                               36,32 5                            38,739                           30,050                             
 Payables: amounts falling due within one year Trade and other payables        ( 1,751 )                          (1,145)                          (832)                              
 Net current assets                                                            34,57 4                            37,594                           29,218                             
 Total assets less current liabilities                                         135,415                            127,113                          121,519                            
 Provisions falling due after one year                                         ( 248 )                            (562)                            (272)                              
 Net assets                                                                    135,167                            126,551                          121,247                            
 Equity attributable to equity holders                                                                                                                                                
 Called-up share capital                                                 8     2,041                              1,833                            1,905                              
 Share premium                                                                 15,958                             76,358                           5,534                              
 Capital redemption reserve                                                    -                                  48                               -                                  
 Unrealised capital reserve                                                    37,67 1                            28,229                           24,828                             
 Realised capital reserve                                                      14,94 1                            23,353                           19,879                             
 Other distributable reserve                                                   64,556                             (3,270)                          69,101                             
 Total equity shareholders’ funds                                              135,167                            126,551                          121,247                            
                                                                                                                                                                                      
 Basic and diluted net asset value per share (pence)*                          7 6.02                             78.69                            72.92                              

* excluding treasury shares

Comparative figures have been extracted from the unaudited Half-yearly
Financial Report for the six months ended 30 June 2022 and the audited
statutory accounts for the year ended 31 December 2022.

The accompanying notes form an integral part of this Half-yearly Financial
Report.

These Financial Statements were approved by the Board of Directors and
authorised for issue on 21 September 2023 and were signed on its behalf by

Clive Richardson
Chairman
Company number: 04114310

Condensed statement of changes in equity

                                                                      Called up share capital  Share premium  Capital redemption reserve  Unrealised capit al reserve  Realised capital reserve*  Other distributable reserve*  Total        
                                                                      £’000                    £’000          £’000                       £’000                        £’000                      £’000                         £’000        
 As at 1 January 202 3                                                1,905                    5,534          -                           24,828                       19,879                     69,101                        121,247      
 Profit/(loss) and total comprehensive income for the period          -                        -              -                           8,787                        (88 2 )                    25 4                          8,159        
 Transfer of previously unrealised losses on disposal of investments  -                        -              -                           4,05 6                       (4,05 6 )                  -                             -            
 Purchase of own shares for treasury                                  -                        -              -                           -                            -                          (1, 56 1 )                    ( 1, 56 1 )  
 Issue of equity                                                      136                      10,700         -                           -                            -                          -                             10,836       
 Cost of issue of equity                                              -                        ( 276 )        -                           -                            -                          -                             ( 276 )      
 Dividends paid                                                       -                        -              -                           -                            -                          ( 3,238 )                     ( 3, 238 )   
 A s a t 30 June 20 2 3                                               2,041                    15,958         -                           37,67 1                      14,94 1                    64,556                        135,167      
 As at 1 January 2022                                                 1,536                    52,687         48                          33,469                       18,259                     995                           106,994      
 Profit/(loss) and total comprehensive income for the period          -                        -              -                           (838)                        692                        163                           17           
 Transfer of previously unrealised gains on disposal of investments   -                        -              -                           (4,402)                      4,402                      -                             -            
 Purchase of own shares for treasury                                  -                        -              -                           -                            -                          (1,188)                       (1,188)      
 Issue of equity                                                      297                      24,273         -                           -                            -                          -                             24,570       
 Cost of issue of equity                                              -                        (602)          -                           -                            -                          -                             (602)        
 Dividends paid                                                       -                        -              -                           -                            -                          (3,240)                       (3,240)      
 As at 30 June 2022                                                   1,833                    76,358         48                          28,229                       23,353                     (3,270)                       126,551      
 As at 1 January 2022                                                 1,536                    52,687         48                          33,469                       18,259                     995                           106,994      
 (Loss)/profit and total comprehensive income for the year            -                        -              -                           (6,498)                      (523)                      720                           (6,301)      
 Transfer of previously unrealised gains on disposal of investments   -                        -              -                           (2,143)                      2,143                      -                             -            
 Purchase of shares for treasury                                      -                        -              -                           -                            -                          (2,512)                       (2,512)      
 Issue of equity                                                      369                      29,943         -                           -                            -                          -                             30,312       
 Cost of issue of equity                                              -                        (739)          -                           -                            -                          -                             (739)        
 Cancellation of share premium and capital redemption reserve         -                        (76,357)       (48)                        -                            -                          76,405                        -            
 Dividends paid                                                       -                        -              -                           -                            -                          (6,507)                       (6,507)      
 As at 31 December 2022                                               1,905                    5,534          -                           24,828                       19,879                     69,101                        121,247      

*Included within these reserves are amounts of £28,406,000 (30 June 2022:
£17,686,000; 31 December 2022: £31,907,000) which are considered
distributable at 30 June 2023. Over the next three years an additional
£41,966,000 will become distributable. This is due to the HMRC requirement
that the Company cannot use capital raised in the past three years to make a
payment or distribution to shareholders.

Condensed statement of cash flows

                                                     Unaudited six months ended 30 June 20 2 3 £’000     Unaudited six months ended 30 June 2022 £’000     Audited year ended 31 December 2022 £’000     
 Cash flow from operating activities                                                                                                                                                                     
 Loan stock income received                          484                                                 767                                               1,199                                         
 Dividend income received                            -                                                   80                                                132                                           
 Income from fixed term funds received               95                                                  9                                                 59                                            
 Deposit interest received                           147                                                 9                                                 50                                            
 Investment management fee paid                      (1, 204 )                                           (1,196)                                           (2,586)                                       
 Other cash payments                                 (3 76 )                                             (302)                                             (591)                                         
 Corporation tax paid                                -                                                   -                                                 -                                             
 Net cash flow generated from operating activities   ( 854 )                                             (633)                                             (1,737)                                       
                                                                                                                                                                                                         
                                                                                                                                                                                                         
 Cash flow from investing activities                                                                                                                                                                     
 Purchase of fixed asset investments                 ( 435 )                                             (6,308)                                           (16,108)                                      
 Proceeds from disposals of fixed asset investments  1,257                                               8,337                                             9,530                                         
 Net cash flow generated from investing activities   822                                                 2,029                                             (6,578)                                       
                                                                                                                                                                                                         
                                                                                                                                                                                                         
 Cash flow from financing activities                                                                                                                                                                     
 Issue of share capital                              10,054                                              23,413                                            28,484                                        
 Cost of issue of equity                             -                                                   (18)                                              (36)                                          
 Dividends paid*                                     (2, 72 3 )                                          (2,671)                                           (5,387)                                       
 Purchase of own shares (including costs)            (9 87 )                                             (963)                                             (2,513)                                       
 Net cash flow generated from financing activities   6,344                                               19,761                                            20,548                                        
                                                                                                                                                                                                         
 Increase in cash in bank and at hand                6,312                                               21,157                                            12,233                                        
 Cash in bank and at hand at start of period         26,594                                              14,361                                            14,361                                        
 Cash in bank and at hand at end of period           32,906                                              35,518                                            26,594                                        

*The dividends paid shown in the cash flow are different to the dividends
disclosed in note 6 as a result of the non-cash effect of the Dividend
Reinvestment Scheme.

Notes to the condensed Financial Statements

1. Basis of preparation
The condensed Financial Statements have been prepared in accordance with
applicable United Kingdom law and accounting standards, including Financial
Reporting Standard 102 (“FRS 102”), and with the Statement of Recommended
Practice “Financial Statements of Investment Trust Companies and Venture
Capital Trusts” (“SORP”) issued by The Association of Investment
Companies (“AIC”). The Financial Statements have been prepared on a going
concern basis.

The preparation of the Financial Statements requires management to make
judgements and estimates that affect the application of policies and reported
amounts of assets, liabilities, income and expenses. The most critical
estimates and judgements relate to the determination of carrying value of
investments at fair value through profit and loss (“FVTPL”) in accordance
with FRS 102 sections 11 and 12. The Company values investments by following
the International Private Equity and Venture Capital Valuation (“IPEV”)
Guidelines as updated in 2022 and further detail on the valuation techniques
used are outlined in note 2 below.

Company information can be found on page 4 of the Half-yearly Financial
Report.

2. Accounting policies
Fixed investments
The Company’s business is investing in financial assets with a view to
profiting from their total return in the form of income and capital growth.
This portfolio of financial assets is managed, and its performance evaluated
on a fair value basis, in accordance with a documented investment policy, and
information about the portfolio is provided internally on that basis to the
Board.

In accordance with the requirements of FRS 102, those undertakings in which
the Company holds more than 20% of the equity as part of an investment
portfolio are not accounted for using the equity method. In these
circumstances the investment is measured at Fair Value Through Profit and Loss
(“FVTPL”).

Upon initial recognition (using trade date accounting) investments, including
loan stock, are classified by the Company as FVTPL and are included at their
initial fair value, which is cost (excluding expenses incidental to the
acquisition which are written off to the Income statement).

Subsequently, the investments are valued at ‘fair value’, which is
measured as follows:
* Investments listed on recognised exchanges are valued at their bid prices at
the end of the accounting period or otherwise at fair value based on published
price quotations.


* Unquoted investments, where there is no active market, are valued using an
appropriate valuation technique in accordance with the IPEV Guidelines.
Indicators of fair value are derived using established methodologies including
earnings multiples, revenue multiples, the level of third party offers
received, cost or prices of recent investment rounds, net assets and industry
valuation benchmarks. Where the price of recent investment is used as a
starting point for estimating fair value at subsequent measurement dates, this
has been benchmarked using an appropriate valuation technique permitted by the
IPEV guidelines.


* In situations where the cost or price of recent investment is used,
consideration is given to the circumstances of the portfolio company since
that date in determining fair value. This includes consideration of whether
there is any evidence of deterioration or strong definable evidence of an
increase in value. In the absence of these indicators, other valuation
techniques are employed to conclude on the fair value as of the measurement
date. Examples of events or changes that could indicate a diminution include:

          * the performance and/or prospects of the underlying business are
significantly below the expectations on which the investment was based; or
* a significant adverse change either in the portfolio company’s business or
in the technological, market, economic, legal or regulatory environment in
which the business operates; or
* market conditions have deteriorated, which may be indicated by a fall in the
share prices of quoted businesses operating in the same or related sectors.
Investments are recognised as financial assets on legal completion of the
investment contract and are de-recognised on legal completion of the sale of
an investment.

Dividend income is not recognised as part of the fair value movement of an
investment but is recognised separately as investment income through the other
distributable reserve when a share becomes ex-dividend.

Current assets and payables
Receivables (including debtors due after more than one year), payables and
cash are carried at amortised cost, in accordance with FRS 102. Debtors due
after more than one year meet the definition of a financing transaction and
are held at amortised cost, and interest will be recognised through capital
over the credit period using the effective interest method. There are no
financial liabilities other than payables.

Provisions 
Provisions relate to the performance incentive fee payable to the Manager. The
provision requires management to make judgements and estimates under the Basis
of Preparation. The performance incentive fee provision is the best estimate
of the probable amounts payable in respect of the five-year performance
measurement period for the performance incentive fee. The most significant
assumption when calculating this amount, is that of future performance. This
has been calculated by reference to the Company’s five year rolling historic
returns and has been corroborated by a portfolio return analysis using
appropriate benchmarks.

Investment income
Equity income
Dividend income is included in revenue when the investment is quoted
ex-dividend.

Unquoted loan stock and other preferred income
Fixed returns on non-equity shares and debt securities are recognised when the
Company’s right to receive payment and expected settlement is established.
Where interest is rolled up and/or payable at redemption then it is recognised
as income unless there is reasonable doubt as to its receipt.

Fixed term funds income
Funds income is recognised on an accruals basis using the agreed rate of
interest.

Bank deposit income
Interest income is recognised on an accruals basis using the rate of interest
agreed with the bank.

Investment management fee, performance incentive fee and expenses
All expenses have been accounted for on an accruals basis. Expenses are
charged through the other distributable reserve except the following which are
charged through the realised capital reserve:
* 90% of management fees and 100% of performance incentive fees, if any, are
allocated to the realised capital reserve.
* expenses which are incidental to the purchase or disposal of an investment
are charged through the realised capital reserve.
Taxation
Taxation is applied on a current basis in accordance with FRS 102. Current tax
is tax payable or refundable in respect of the taxable profit or tax loss for
the current period or past reporting periods using the tax rates and laws that
have been enacted or substantively enacted at the financial reporting date.
Taxation associated with capital expenses is applied in accordance with the
SORP.

Deferred tax is provided in full on all timing differences at the reporting
date. Timing differences are differences between taxable profits and total
comprehensive income as stated in the Financial Statements that arise from the
inclusion of income and expenses in tax assessments in periods different from
those in which they are recognised in the Financial Statements. As a VCT the
Company has an exemption from tax on capital gains. The Company intends to
continue meeting the conditions required to obtain approval as a VCT for the
foreseeable future. The Company, therefore, should have no material deferred
tax timing differences arising in respect of the revaluation or disposal of
investments and the Company has not provided for any deferred tax.

Share capital and reserves
Called-up share capital
This accounts for the nominal value of the shares.

Share premium 
This accounts for the difference between the price paid for the Company’s
shares and the nominal value of those shares, less issue costs.

Capital redemption reserve
This reserve accounts for amounts by which the issued share capital is
diminished through the repurchase and cancellation of the Company’s own
shares.

Unrealised capital reserve
Increases and decreases in the valuation of investments held at the period end
against cost are included in this reserve.

Realised capital reserve
The following are disclosed in this reserve:
* gains and losses compared to cost on the realisation of investments, or
permanent diminutions in value (including gains recognised on the realisation
of investments where consideration is deferred that are not distributable as a
matter of law);
* finance income in respect of the unwinding of the discount on deferred
consideration that is not distributable as a matter of law;
* expenses, together with the related taxation effect, charged in accordance
with the above policies; and
* dividends paid to equity holders where paid out by capital.
Other distributable reserve
The special reserve, treasury share reserve and the revenue reserve were
combined in 2012 to form a single reserve named “other distributable
reserve”.

This reserve accounts for movements from the revenue column of the Income
statement, the payment of dividends, the buy-back of shares and other
non-capital realised movements.

Dividends
Dividends by the Company are accounted for in the period in which the
liability to make the payment has been established or approved at the Annual
General Meeting.

Segmental reporting
The Directors are of the opinion that the Company is engaged in a single
operating segment of business, being investment in smaller early stage
companies principally based in the UK.

3.        Gains/(losses) on investments

                                                       Unaudited six months ended 30 June 20 2 3 £’000     Unaudited six months ended 30 June 2022 £’000     Audited year ended 31 December 2022 £’000     
 Unrealised gains/(losses) on fixed asset investments  8,787                                               (838)                                             (6,498)                                       
 Realised gains on fixed asset investments             367                                                 2,238                                             1,647                                         
 Unwinding of discount on deferred consideration       208                                                 179                                               371                                           
                                                       9,362                                               1,579                                             (4,480)                                       

4.        Investment income

                               Unaudited six months ended 30 June 20 2 3 £’000     Unaudited six months ended 30 June 2022 £’000     Audited year ended 31 December 2022 £’000     
 Loan stock interest           448                                                 505                                               978                                           
 Bank deposit interest         147                                                 9                                                 50                                            
 Income from fixed term funds  95                                                  9                                                 59                                            
 Dividend income               23                                                  96                                                544                                           
                               713                                                 619                                               1,631                                         
                                                                                                                                                                                   

5.        Investment Manager’s fees

                                                                         Unaudited six months ended 30 June 20 2 3 £’000     Unaudited six months ended 30 June 2022 £’000     Audited year ended 31 December 2022 £’000     
 Investment management fee charged to revenue                            138                                                 129                                               253                                           
 Investment management fee charged to capital                            1, 240                                              1,163                                             2,269                                         
 Total investment management fee                                         1, 378                                              1,292                                             2,522                                         
                                                                                                                                                                                                                             
 Movement in provision for performance incentive fee charged to capital  21 7                                                562                                               272                                           
                                                                         1, 59 5                                             1,854                                             2,794                                         

Further details of the Management agreement under which the investment
management fee and performance incentive fee are paid are given in the
Strategic report on page 19 of the Annual Report and Financial Statements for
the year ended 31 December 2022.

During the period, services for a total value of £1,478,000 (30 June 2022:
£1,392,000; 31 December 2022: £2,722,000) were purchased by the Company from
Albion Capital Group LLP (“Albion Capital”) comprising £1,378,000 of
management fees (30 June 2022: £1,292,000; 31 December 2022: £2,522,000) and
£100,000 of administration fees (30 June 2022: £100,000; 31 December 2022:
£200,000). At the financial period end, the amount due to Albion Capital in
respect of these services disclosed as accruals was £822,000 (administration
fee accrual £50,000, management fee accrual £772,000) (30 June 2022:
£807,000; 31 December 2022: £647,000).

Currently a best estimate provision of £489,000 has been calculated and
included in relation to potential performance incentive fees which arise from
performance to 30 June 2023, which would become payable over the periods to 31
December 2027. Within this amount, £241,000 is included in payables falling
due within one year in relation to the first payment calculated on the
five-year period ending 31 December 2023, which is payable after the adoption
of the audited accounts at the 2024 AGM based on actual year end performance.
Further details can be found in note 9.

During the period, the Company was not charged by Albion Capital in respect of
Patrick Reeve’s services as a Director (30 June 2022 and 31 December 2022:
£nil).

Albion Capital, its partners and staff (including Patrick Reeve), held
1,636,367 Ordinary shares in the Company as at 30 June 2023.

Albion Capital is, from time to time, eligible to receive arrangement fees and
monitoring fees from portfolio companies. During the period to 30 June 2023,
fees of £81,000 attributable to the investments of the Company were received
by Albion Capital pursuant to these arrangements (30 June 2022: £132,000; 31
December 2022: £345,000).

 6. Dividends                                                                            Unaudited six months ended 30 June 20 2 3 £’000     Unaudited six months ended 30 June 2022 £’000     Audited year ended 31 December 2022 £’000     
 First dividend of 1.82p per share paid on 30 June 2023 (30 June 2022: 2.02p per share)  3,2 38                                              3,240                                             3,240                                         
 Second dividend of 1.97p per share paid on 30 December 2022                             -                                                   -                                                 3,267                                         
                                                                                         3,2 38                                              3,240                                             6,507                                         

The Directors have declared a dividend of 1.90 pence per Ordinary share (total
approximately £3,378,000) payable on 29 December 2023, to shareholders on the
register on 8 December 2023.

7.        Basic and diluted return/(loss) per share

                                                                  Unaudited six months ended 30 June 20 2 3     Unaudited six months ended 30 June 2022         Audited year ended 31 December 2022       
                                                                  Revenue                Capital                Revenue                         Capital         Revenue                     Capital       
 Profit/(loss) attributable to equity shares (£’000)              25 4                   7,90 5                 163             (146)                           721           (7,022)                     
 Weighted average shares in issue (adjusted for treasury shares)  172,268,564                                   149,501,675                                     155,471,219                               
 Return/(loss) attributable per equity share (pence)              0.1 5                  4.59                   0.11            (0.10)                          0.46          (4.51)                      

The weighted average number of shares is calculated after adjusting for
treasury shares of 26,353,527 (30 June 2022: 22,449,076; 31 December 2022:
24,236,401).

There are no convertible instruments, derivatives or contingent share
agreements in issue, and therefore no dilution affecting the return/(loss) per
share. The basic return/(loss) per share is therefore the same as the diluted
return/(loss) per share.

8.         Share capital

 Allotted, called up and fully paid shares of 1 penny each  Unaudited 30 June 202 3  Unaudited 30 June 2022  Audited 31 December 2022  
 Number of shares                                           204, 149,764             183,280,301             190,510,554               
 Nominal value of allotted shares (£’000)                   2,04 1                   1,833                   1,905                     
 Voting rights (number of shares net of treasury shares)    177,796,237              160,831,225             166,274,153               

During the period to 30 June 2023 the Company purchased 2,117,126 Ordinary
shares (nominal value £21,171) for treasury at a cost of £1,561,000. The
total number of Ordinary shares held in treasury as at 30 June 2023 was
26,353,527 (30 June 2022: 22,449,076; 31 December 2022: 24,236,401)
representing 12.9% of the Ordinary shares in issue as at 30 June 2023.

Under the terms of the Dividend Reinvestment Scheme, the following new
Ordinary shares of nominal value 1 penny each were allotted during the period
to 30 June 2023:

 Date of allotment  Number of shares allotted  Aggregate nominal value of shares (£’000)     Issue price (pence per share)  Net  invested (£’000)     Opening market price on allotment date (pence per share)  
 30 June 2023       685,420                    7                                             76.77                          506                       73.00                                                     

Under the terms of the Albion VCTs Prospectus Top Up Offers 2022/23, the
following new Ordinary shares, of nominal value 1 penny each, were allotted
during the period to 30 June 2023:

 Date of allotment  Number of shares allotted  Aggregate nominal value of shares (£’000)     Issue price (pence per share)  Net consideration received (£’000)     Opening market price on allotment date (pence per share)  
 31 March 2023      12,395,704                 124                                           79.60                          9,621                                  74.00                                                     
 14 April 2023      95,387                     1                                             78.80                          74                                     74.00                                                     
 14 April 2023      31,564                     -                                             79.20                          24                                     74.00                                                     
 14 April 2023      431,135                    4                                             79.60                          335                                    74.00                                                     
                    12,953,790                 129                                                                          10,054                                                                                           

9.         Provisions and significant estimates
In accordance with the AIC SORP and FRS102, a provision for a performance
incentive fee (“PIF") is required to be estimated and accounted for in the
financial statements. The PIF is calculated on a five-year rolling average
performance basis, with a 5% hurdle applied to the opening net asset value
each year, which is in line with our current dividend target. The first five
year performance period will take into account the audited results of the five
years ending 31 December 2023.

Any PIF will only be paid on actual year end audited results, and this
provision is the Board’s best estimate of the potential obligation relating
to the inclusion of realised performance from 1 January 2019 to 30 June 2023
in any future five-year rolling periods.

 Movement in provision           Unaudited six months ended 30 June 20 2 3 £’000     Unaudited six months ended 30 June 2022 £’000     Audited year ended 31 December 2022 £’000     
 Opening provision               272                                                 -                                                 -                                             
 Movement in provision           217                                                 562                                               272                                           
 Closing provision               489                                                 562                                               272                                           
                                                                                                                                                                                     
 Payable within one year:        241                                                 -                                                 -                                             
 Payable in more than one year:  248                                                 562                                               272                                           

The most significant assumption when calculating this amount, is that of
future performance. Results for the period from 1 January 2019 to 30 June
2023 are included in the calculation; a forecast has been used for current
year performance and future years assume performance is achieved in line with
the five year historic rolling average. The provision included in the
financial statements has been calculated on this basis and has been
corroborated by a portfolio return analysis using appropriate benchmarks.
Performance fees are only paid on final audited results for a five year
period.

The average return per annum over each rolling five year period since the
Company’s inception in 2000 to the date of approval of the new performance
fee arrangements was 5.85%. This smooths the performance through the various
economic events and cycles seen since inception. This has resulted in a
provision of £489,000 at 30 June 2023.

10.        Commitments and contingencies
As at 30 June 2023, the Company had no financial commitments in respect of
investments (30 June 2022 and 31 December 2022: £nil).

There are no contingencies or guarantees of the Company as at 30 June 2023 (30
June 2022 and 31 December 2022: £nil).

11.        Post balance sheet events
There have been no material post balance sheet events since 30 June 2023.

12.        Related party transactions
Other than transactions with the Manager as disclosed in note 5, there are no
other related party transactions requiring disclosure.

13.        Going concern 
The Board has conducted a detailed assessment of the Company’s ability to
meet its liabilities as they fall due. Cash flow forecasts are updated and
discussed quarterly at Board meetings and have been stress tested to allow for
the forecast impact of the current economic climate and increasingly volatile
geopolitical backdrop. The Board has revisited and updated its assessment of
liquidity risk and concluded that it remains unchanged since the last Annual
Report and Financial Statements. Further details can be found on page 91 of
those accounts.

The portfolio of investments is diversified in terms of sector and the major
cash outflows of the Company (namely investments, dividends and share
buy-backs) are within the Company’s control. Accordingly, after making
diligent enquiries, the Directors have a reasonable expectation that the
Company has adequate cash and liquid resources to continue in operational
existence for the foreseeable future. For this reason, the Directors have
adopted the going concern basis in preparing this Half-yearly Financial Report
and this is in accordance with the Guidance on Risk Management, Internal
Control and Related Financial and Business Reporting issued by the Financial
Reporting Council in September 2014, and the subsequent updated Going concern,
risk and viability guidance issued by the FRC in 2021.

14.        Other information
The information set out in this Half-yearly Financial Report does not
constitute the Company’s statutory accounts within the terms of section 434
of the Companies Act 2006 for the periods ended 30 June 2023 and 30 June 2022
and is unaudited. The information for the year ended 31 December 2022 does not
constitute statutory accounts within the terms of section 434 of the Companies
Act 2006 and is derived from the statutory accounts for that financial year,
which have been delivered to the Registrar of Companies. The Auditor reported
on those accounts; their report was unqualified and did not contain a
statement under s498 (2) or (3) of the Companies Act 2006.

15.        Publication
This Half-yearly Financial Report is being sent to shareholders and copies
will be made available to the public at the registered office of the Company,
Companies House, the National Storage Mechanism and also electronically at
www.albion.capital/funds/AATG, where the Report can be accessed from the
'Financial Reports and Circulars' section.

Attachment
*     Current portfolio sector allocation
(https://ml-eu.globenewswire.com/Resource/Download/4f998f63-632e-4ffa-92a2-6f2e35c2285f)

Recent news on Albion Technology & General VCT

See all news